Physician profile
Edwin E Taylor
NPI 1790765915
$4,516.62
in general payments reported to CMS, 2019-2025
34 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $378 · 2020: $317 · 2021: $444 · 2022: $450 · 2023: $870 · 2024: $932 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,927.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $815.06 | 2019-2025 | Airsupra, Farxiga |
| Abbvie INC. | $506.65 | 2021-2025 | Vraylar, Ubrelvy |
| Pfizer INC. | $498.88 | 2019-2025 | |
| Novo Nordisk INC | $467.60 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $406.45 | 2019-2025 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $374.99 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $245.74 | 2019-2025 | Repatha, Evenity, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $185.36 | 2023-2025 | |
| Exact Sciences Corporation | $90.42 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $90.05 | 2024-2025 | Xifaxan |
| Cranial Technologies, INC | $79.60 | 2024-2025 | Doc Band |
| Merck Sharp & Dohme LLC | $77.36 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Avadel Cns Pharmaceuticals, LLC | $64.87 | 2025 | Lumryz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.04 | 2020-2024 | Jardiance |
| Abbott Laboratories | $44.68 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.80 | 2022-2023 | Xarelto |
| Biohaven Pharmaceuticals, INC. | $40.89 | 2021 | |
| Shield Therapeutics INC | $37.92 | 2025 | |
| Corium, LLC | $34.41 | 2025 | Azstarys |
| Azurity Pharmaceuticals, INC. | $33.31 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.51 | 2022 | |
| Allergan, INC. | $30.44 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.14 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $30.10 | 2023-2024 | Voquezna |
| Shire North American Group INC | $26.73 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.68 | 2019 | |
| Dexcom, INC. | $23.99 | 2023 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $23.66 | 2019 | |
| Verona Pharma, INC. | $19.85 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $18.45 | 2024 | |
| Sanofi Pasteur INC. | $17.86 | 2020 | |
| Tris Pharma INC | $16.18 | 2023 | Dyanavel Xr |
| Eisai INC. | $15.17 | 2020 | |
| Genentech USA, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.